Glyree MV1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The synergistic action of these three agents targets multiple pathophysiological defects of type 2 diabetes, offering comprehensive glycemic regulation. Glyree MV1 Tablet PR is typically prescribed as part of a balanced diet and exercise regimen to achieve optimal blood glucose levels. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly due to Glimepiride. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. This combination tablet provides an effective option for patients requiring multi-mechanistic glucose control.